© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 7, 474-475,
April 3, 2002
© 2002 Oxford University Press
NEWS |
Upstaging Tamoxifen? New Classes of Drugs Emerging for Breast Cancer
The success of tamoxifen, once a failed contraceptive drug, has ushered in a boom of research into new therapies that may soon upstage tamoxifen itself, researchers say.
As a breast cancer treatment, the 31-year-old tamoxifen may be surpassed by new classes of drugs such as aromatase inhibitors and novel estrogen receptor down regulators.
Tamoxifen, approved for reducing the risk to breast cancer in high-risk women 4 years ago, is now competing with a younger cousin, raloxifene, purported to have fewer side effects than tamoxifen. Raloxifene is already battling with highly tailored third generation selective estrogen receptor modulators (SERMs).
Some researchers think of them as designer endocrines; others label them hormonal smart bombs that bind, block, or destroy production or use of estrogen. Whatever the method, the intent is the same: manipulation of estrogen in a womans